BIOLASE Technology, Inc. Chief Financial Officer Frederick D. Furry to Add Chief Operating Officer Role

IRVINE, CA--(Marketwire - October 19, 2011) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the World’s leading dental laser manufacturer and distributor, announced today that Chief Financial Officer Frederick D. Furry has been appointed to Chief Operating Officer, effective immediately. Furry will continue in his role as Chief Financial Officer and reports directly to Chief Executive Officer Federico Pignatelli.

“Fred has been instrumental in the turnaround efforts at BIOLASE over the past year, and broadening his responsibilities to include operations will allow him to bring even more value to the organization,” said Pignatelli. “Both I and the Board have every confidence that Fred’s background and proven executive capabilities make this expansion in duties the right move as we continue to grow and develop new products and markets.”

Furry, 43, a resident of Huntington Beach, joined BIOLASE as Chief Financial Officer in November 2010. He is a certified public accountant and has more than 18 years experience working for accounting firms which include Windes & McClaughry, Pricewaterhouse Coopers and Miller, Kaplan, Arase & Co.

Furry began his 11-year tenure at Windes & McClaughry, a regional accounting firm and recognized leader in the field of public accounting, as an audit and assurance manager in 1998. He was promoted to Partner in 2004. Prior to this, he was an audit manager at Pricewaterhouse Coopers, a global public accounting firm and a leader in the industry.

He holds a B.S. degree in business administration and an M.B.A. degree in Management & Accounting from the University of California, Riverside.

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World’s leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company’s laser products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company’s actual results to differ materially from the statements contained herein, and are described in the Company’s reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.